Add to Twitter
U.S. Food & Drug Administration Accepts Takeda’s Biologics License Application for a Subcutaneous Formulation of Vedolizumab (Entyvio®) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
• An additional treatment modality would provide more flexibility in how patients receive vedolizumab, a biologic with a gut-selective mode of action

• Vedolizumab set to be the only maintenance therapy to offer the option of intravenous or subcutaneous formulations for patients with ulcerative colitis